Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Foundations Investment Advisors LLC

Foundations Investment Advisors LLC lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 15,352 shares of the biopharmaceutical company’s stock after purchasing an additional 265 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $868,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Algert Global LLC acquired a new position in Bristol-Myers Squibb during the 2nd quarter worth approximately $328,000. Quarry LP acquired a new position in shares of Bristol-Myers Squibb during the second quarter worth $47,000. Founders Financial Alliance LLC boosted its stake in shares of Bristol-Myers Squibb by 18.1% in the second quarter. Founders Financial Alliance LLC now owns 8,390 shares of the biopharmaceutical company’s stock valued at $348,000 after purchasing an additional 1,287 shares during the period. Birmingham Capital Management Co. Inc. AL grew its holdings in Bristol-Myers Squibb by 3.2% during the 2nd quarter. Birmingham Capital Management Co. Inc. AL now owns 45,141 shares of the biopharmaceutical company’s stock valued at $1,875,000 after purchasing an additional 1,416 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in Bristol-Myers Squibb during the 2nd quarter worth $55,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on BMY shares. Bank of America restated a “neutral” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Citigroup raised their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and increased their target price for the company from $55.00 to $73.00 in a research note on Tuesday, November 12th. TD Cowen lifted their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Finally, Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research note on Wednesday, November 13th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $56.60.

Insiders Place Their Bets

In related news, EVP Samit Hirawat acquired 1,830 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Stock Performance

BMY stock opened at $59.11 on Thursday. The stock’s fifty day moving average is $57.56 and its two-hundred day moving average is $52.97. The stock has a market capitalization of $119.88 billion, a price-to-earnings ratio of -16.46, a PEG ratio of 2.02 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.49 by $0.31. The firm had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. Bristol-Myers Squibb’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.00 EPS. On average, research analysts predict that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be given a $0.62 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a yield of 4.20%. The ex-dividend date of this dividend is Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -69.08%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.